文献速递组学、生物样本库与精准医学基础与转化研究

纵向血浆蛋白质组学可预测肌萎缩侧索硬化临床转化

Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS.
PubMed 文献 · Nat Med · 2026-07-27

该纵向Olink Explore高通量蛋白质组研究纳入33例转化者、35例ALS患者、10例症状前致病变异携带者和59例对照的516份系列血浆样本,识别出92个在转化前浓度变化的蛋白,并构建19个蛋白核心组合,可在0.5至5年时间范围内预测临床转化,交叉验证AUC为0.80-0.89,转化时间估计的平均绝对误差为1.6年,部分结果在UK Biobank中重复验证。

要点

  • 92个血浆蛋白在ALS临床转化前浓度已发生改变。
  • 19蛋白组合可预测0.5-5年内转化,交叉验证AUC 0.80-0.89。
  • 该组合估计转化时间的平均绝对误差为1.6年,优于单用NEFL。

核心结论

  • 纵向血浆蛋白质组学可识别ALS临床转化前的蛋白变化并构建预测组合。
  • 19蛋白组合能预测0.5至5年时间范围内的临床转化并估计转化时间。

研究设计与样本

  • 纵向Olink Explore高通量蛋白质组研究,纳入516份系列血浆样本。
  • 样本来自33例转化者、35例ALS患者、10例症状前致病变异携带者和59例对照。

主要发现

  • 识别出92个在临床转化前浓度发生变化的蛋白。
  • 19蛋白核心组合预测转化的交叉验证AUC为0.80-0.89。
  • 该组合估计转化时间的平均绝对误差为1.6年。
  • UK Biobank数据部分重复验证了NEFL、EDA2R和CA3等蛋白的症状前升高。
  • 多蛋白组合在估计转化时间上优于单用NEFL。

临床怎么用

  • 基于纵向血浆蛋白质组数据的新易感性/风险生物标志物组合有助于ALS预防试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The study of pre-symptomatic amyotrophic lateral sclerosis (ALS) and the design of disease prevention trials are greatly hampered by our inability to predict which unaffected carriers of ALS-associated pathogenic variants will phenoconvert to clinically manifest disease and when. In this longitudinal Olink Explore, high-throughput, proteomic study, 516 serially collected plasma samples from 33 phenoconverters, 35 patients with ALS, 10 pre-symptomatic pathogenic variant carriers and 59 controls were included. Here we identified 92 proteins with concentrations that changed before phenoconversion; characterized the longitudinal trajectory of these proteins and identified a core panel of 19 proteins which, collectively, predicted phenoconversion over the 0.5-year to 5-year time horizons (crossvalidated areas under the curve 0.80-0.89) and yielded estimates of time to phenoconversion with a mean absolute error of 1.6 years. These findings were partially replicated in UK Biobank data, confirming pre-symptomatic increases in several proteins (for example, NEFL, EDA2R and CA3) and that a multi-protein panel outperformed NEFL alone in estimating time to phenoconversion. This work sheds light on the biology of pre-symptomatic ALS. Moreover, our identification of a panel of new susceptibility/risk biomarkers based on empirical longitudinal data furthers the ultimate goal of ALS prevention.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Ran X, Wuu J, Qin ZS, et al. Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS. Nat Med. 2026. PMID: 42509371. doi:10.1038/s41591-026-04528-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。